Business Wire

CA-TRIVVER

14.5.2018 10:02:10 CEST | Business Wire | Press release

Share
Trivver Launches Token Sale to Encourage Adoption and Development of Extended Reality Technology

Trivver , the premiere advertising exchange for Extended Reality (XR) environments including 3D, virtual reality, mixed reality and augmented reality, today announced that it will launch the sale of up to 100 million Trivver Tokens (TRVR) to accelerate the adoption, commercialization and monetization of XR technology across devices and industries for all stakeholders in the ecosystem – including content publishers, advertisers, brands, agencies and consumers.

Current 2D advertising tactics like pop-ups, banners, video and interstitials are highly disruptive to immersive XR experiences, leading to limited advertiser adoption of XR and reduced monetization opportunities for XR developers and publishers. Placing ads organically within the natural settings of XR environments is the answer, but the current processes that developers, publishers and advertisers use to execute this strategy is tedious and costly, as ads and objects need to be manually resized to fit each unique location. With Trivver’s suite of patented technology, including its core Smart Object Technology, developers are able to create and deliver native advertising directly into XR environments. This approach enables advertisers to create contextual, integrated XR ad campaigns to engage consumers in a unique and impactful way and gives publishers the opportunity to efficiently monetize their XR content.

“We believe in the exponential possibilities of XR and in the profound, lasting and global impact of this technology,” said Joel LaMontagne, CEO of Trivver. “We are passionate about driving XR adoption among consumers and within the enterprise. Our goal is to enable publishers and developers in the XR space to fund themselves through advertising and encourage the improvement of technology that enhances XR experiences for consumers. We’re also making it easier for advertisers to promote their brand in the XR space through seamless product placement – delivering relevant and interesting content to engage their users.”

In order to drive XR adoption and momentum, Trivver launched its pre-sale of TRVR tokens, which can be purchased with a bonus until June 5, 2018. The public token sale begins on June 8, 2018 and will close on July 7, 2018. The public sale will aim to raise $35 million, with the pre-sale accounting for up to $5 million.

Token Sale Details:

  • Under the terms of the sale, 1 ETH is equivalent to 750 TRVR (1 TRVR ~ 0.00133 ETH) and a hard cap of 100 million TRVR tokens are available for purchase of the finite supply of 200 million total TRVR.
  • All available TRVR will be issued during the distribution period, of which, 50 percent will be allocated to the public and 50 percent will be allocated to the reserve to be held by the company and used to stimulate growth in the Trivver XR advertising ecosystem by rewarding participants with TRVR.
  • All TRVR not distributed will be burned.

TRVR is the currency for the Smart Object Economy. Trivver’s patented Branded Smart Objects (BSOs) are 3D objects with product information (SKU data, coupons, social media links etc.) that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment. Trivver’s BSOs send valuable viewability and user engagement metrics back to the advertiser that will result in the best ROI.

Trivver launched its token sale in order to accelerate the build out of its Smart Objects catalog and will incentivize developers to participate through a system of rewards and payments of TRVR. Developers can earn TRVR for building and adding smart objects to the catalog. They can also use TRVR to list the smart object in Trivver’s inventory and establish authorship of the object. As the author, developers will receive royalties paid in USD from Trivver whenever revenues are generated by the smart object - from a publisher using it to build XR content or by an advertiser using it for future XR ad campaigns.

The Trivver platform is currently in beta and the company has already seen significant interest, announcing upcoming pilot programs in collaboration with WayFair and Cannon.

To learn more about Trivver and to participate in the token sale, visit: https://www.trivver.com/tokensale or join the conversation on Telegram to speak directly with the project’s founders and developers: https://t.me/trivvertokensale . Download the token sale whitepaper at: https://www.trivver.com/docs/Trivver_Whitepaper.pdf .

About Trivver

Trivver is the premiere advertising exchange for Extended Reality (XR) environments – 3D, virtual reality, mixed reality and augmented reality. The Trivver platform makes creating and deploying 3D interactive branded objects easier, allowing brands to programmatically execute targeted, impactful and scalable XR campaigns.

Trivver’s revolutionary, patented Branded Smart Objects (BSOs) are 3D objects that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment.

The Trivver XR Ad Exchange (XRAE) is a programmatic solution that lets advertisers create, run and monitor a highly targeted XR ad campaign in near real time, on mobile apps and desktop applications. Trivver enables publishers to monetize XR environments with branded content that is native and organic – eliminating pop-ups, banners and interstitials that are disruptive to user experience. The Trivver platform facilitates an organic relationship between brand and consumer.

Contact:

Affect
Nicole Sullivan, 212-398-9680
trivver@affect.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye